[{"abstract": "The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion.", "web_url": "https://www.nytimes.com/2015/11/24/business/dealbook/pfizer-allergan-merger-inversion.html", "snippet": "The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion.", "lead_paragraph": "In phone calls to Washington lawmakers and Obama administration officials, the chief executive of the largest drug maker in the nation had a surprising message: A deal that would allow the company to move its headquarters to Ireland was actually good for the United States.", "print_section": "A", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-articleLarge.jpg", "height": 332, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 332}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-jumbo.jpg", "height": 567, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-superJumbo.jpg", "height": 1134, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbStandard-v3.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbStandard-v3.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24-pfizer-web1/24-pfizer-web1-thumbLarge-v3.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Chief Defends Merger With Allergan as Good for U.S.", "kicker": null, "content_kicker": null, "print_headline": "Chief of Pfizer Defends Merger as Good for U.S.", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "ALLERGAN INC", "rank": 1, "major": "N"}, {"name": "persons", "value": "Picker, Leslie", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "persons", "value": "Gelles, David", "rank": 4, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 5, "major": "N"}, {"name": "persons", "value": "de la Merced, Michael J", "rank": 6, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 7, "major": "N"}, {"name": "subject", "value": "Tax Shelters", "rank": 8, "major": "N"}, {"name": "glocations", "value": "Ireland", "rank": 9, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 10, "major": "N"}, {"name": "subject", "value": "Relocation of Business", "rank": 11, "major": "N"}, {"name": "subject", "value": "Botox (Drug)", "rank": 12, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 13, "major": "N"}, {"name": "glocations", "value": "Dublin (Ireland)", "rank": 14, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 15, "major": "N"}], "pub_date": "2015-11-23T12:29:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Michael J. de la Merced, David Gelles and Leslie Picker", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "David", "middlename": null, "lastname": "Gelles", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}, {"firstname": "Leslie", "middlename": null, "lastname": "Picker", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 3}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/dbb15e51-ccdc-549e-9017-35ea94baf612", "word_count": 1485, "uri": "nyt://article/dbb15e51-ccdc-549e-9017-35ea94baf612"}, {"abstract": "The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers.", "web_url": "https://www.nytimes.com/2015/11/24/business/dealbook/pfizers-huge-deal-could-work-but-with-adverse-effects.html", "snippet": "The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers.", "lead_paragraph": "Pfizer\u2019s $160 billion opus of financial engineering theoretically could pay off.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg", "height": 443, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 443}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-jumbo.jpg", "height": 757, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-superJumbo.jpg", "height": 1478, "width": 2000, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer\u2019s Huge Deal Could Work, but With Adverse Effects", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Treasury Department", "rank": 5, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 6, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 7, "major": "N"}], "pub_date": "2015-11-23T15:30:59+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/b642cca6-ce47-5e5d-8a9d-193dc7b47b8d", "word_count": 386, "uri": "nyt://article/b642cca6-ce47-5e5d-8a9d-193dc7b47b8d"}, {"abstract": "While not technically structured as an inversion, the huge drug merger spurs calls for change.", "web_url": "https://www.nytimes.com/2015/11/24/business/dealbook/pfizer-deal-stokes-washington-concerns-over-tax-policy.html", "snippet": "While not technically structured as an inversion, the huge drug merger spurs calls for change.", "lead_paragraph": "Despite growing pressure in Washington to curb a tax-saving strategy used by American companies, recent proposals by the Treasury Department would not have affected the Pfizer-Allergan merger.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-react-web1/db-react-web1-articleLarge.jpg", "height": 399, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/db-react-web1/db-react-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 399}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-react-web1/db-react-web1-jumbo.jpg", "height": 681, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-react-web1/db-react-web1-superJumbo.jpg", "height": 1362, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-react-web1/db-react-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/db-react-web1/db-react-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/db-react-web1/db-react-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Deal Stokes Washington Concerns Over Tax Policy", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "subject", "value": "Taxation", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "subject", "value": "United States Politics and Government", "rank": 4, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 5, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 6, "major": "N"}, {"name": "persons", "value": "Hatch, Orrin G", "rank": 7, "major": "N"}, {"name": "persons", "value": "Levin, Sander M", "rank": 8, "major": "N"}, {"name": "persons", "value": "Lew, Jacob J", "rank": 9, "major": "N"}, {"name": "persons", "value": "Sanders, Bernard", "rank": 10, "major": "N"}, {"name": "persons", "value": "Obama, Barack", "rank": 11, "major": "N"}], "pub_date": "2015-11-23T18:31:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Liz Moyer", "person": [{"firstname": "Liz", "middlename": null, "lastname": "Moyer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/a074a2c8-fbfd-5c28-97fa-ed09eba60359", "word_count": 940, "uri": "nyt://article/a074a2c8-fbfd-5c28-97fa-ed09eba60359"}, {"abstract": "With an equity value of $152 billion, the merger is the largest since the heady days of 2000.", "web_url": "https://www.nytimes.com/2015/11/24/business/dealbook/how-the-pfizer-allergan-deal-ranks.html", "snippet": "With an equity value of $152 billion, the merger is the largest since the heady days of 2000.", "lead_paragraph": "The huge price tag accorded to the deal between Allergan and Pfizer \u2014 $160 billion in total enterprise value \u2014 is one of the largest in history and the biggest ever among pharmaceutical companies.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-articleLarge.jpg", "height": 393, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 393}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-jumbo.jpg", "height": 671, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-superJumbo.jpg", "height": 1342, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "How the Pfizer-Allergan Deal Ranks", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Vodafone Group Plc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Mannesmann AG", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Time Warner Inc", "rank": 7, "major": "N"}], "pub_date": "2015-11-23T18:49:32+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Leslie Picker", "person": [{"firstname": "Leslie", "middlename": null, "lastname": "Picker", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/47ec9b96-e47c-517c-9f8b-df52fc507d92", "word_count": 275, "uri": "nyt://article/47ec9b96-e47c-517c-9f8b-df52fc507d92"}]